Enliven Therapeutics Inc (ELVN)

Sep 30, 2025

Chart based exit strategy for Enliven Therapeutics Inc.Quarterly Profit Summary & Consistent Growth Equity Picks - newser.com

Sep 30, 2025

Sep 30, 2025

Long term hold vs stop loss in Enliven Therapeutics Inc.Quarterly Risk Review & Weekly Market Pulse Alerts - newser.com

Sep 30, 2025

Sep 30, 2025

Is now a turning point for Enliven Therapeutics Inc.Insider Buying & Stepwise Trade Signal Guides - newser.com

Sep 30, 2025

Sep 29, 2025

Top chart patterns to watch in Enliven Therapeutics Inc.2025 Big Picture & Weekly High Return Opportunities - newser.com

Sep 29, 2025

Sep 29, 2025

Will Enliven Therapeutics Inc. stock recover after recent dropWeekly Trend Recap & Long-Term Safe Investment Plans - newser.com

Sep 29, 2025

Sep 29, 2025

Will Enliven Therapeutics Inc. rebound enough to break even2025 Top Decliners & Weekly High Potential Stock Alerts - newser.com

Sep 29, 2025

Sep 29, 2025

Why retail investors favor Enliven Therapeutics Inc. stockInsider Selling & Free Daily Entry Point Trade Alerts - newser.com

Sep 29, 2025

Sep 29, 2025

Developing predictive dashboards with Enliven Therapeutics Inc. dataJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com

Sep 29, 2025

Sep 28, 2025

What analysts say about Enliven Therapeutics Inc stockGlobal Market Influence & Investment Case Studies - earlytimes.in

Sep 28, 2025

Sep 28, 2025

How to manage a losing position in Enliven Therapeutics Inc.2025 Valuation Update & Precise Buy Zone Identification - newser.com

Sep 28, 2025

Sep 28, 2025

Head-To-Head Analysis: Enliven Therapeutics (NASDAQ:ELVN) vs. Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World

Sep 28, 2025

Sep 27, 2025

Brokerages Set Enliven Therapeutics, Inc. (NASDAQ:ELVN) Price Target at $41.20 - Defense World

Sep 27, 2025

Sep 27, 2025

Enliven Therapeutics Inc Stock Analysis and ForecastFundamental Strength Indicators & Low Risk Wealth Building - Early Times

Sep 27, 2025

Sep 26, 2025

Enliven Therapeutics (NASDAQ:ELVN) Trading 7.2% HigherTime to Buy? - MarketBeat

Sep 26, 2025

Sep 25, 2025

Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CEO Sells 2,800 Shares of Stock - MarketBeat

Sep 25, 2025

Sep 25, 2025

Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 1,500 Shares - MarketBeat

Sep 25, 2025

Sep 25, 2025

Enliven Therapeutics CSO sells $30,045 in shares By Investing.com - Investing.com Canada

Sep 25, 2025

Sep 24, 2025

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Sep 24, 2025

Sep 23, 2025

Enliven Therapeutics CSO sells shares worth $135,697 - Investing.com India

Sep 23, 2025

Sep 23, 2025

Enliven Therapeutics CSO sells shares worth $135,697 By Investing.com - Investing.com Canada

Sep 23, 2025

Sep 23, 2025

Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 7,000 Shares - MarketBeat

Sep 23, 2025

Sep 23, 2025

Samuel Kintz Sells 5,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat

Sep 23, 2025

Sep 23, 2025

Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CEO Sells 1,000 Shares of Stock - MarketBeat

Sep 23, 2025

Sep 22, 2025

Enliven Therapeutics, Inc. $ELVN Shares Purchased by Goldman Sachs Group Inc. - MarketBeat

Sep 22, 2025

Sep 22, 2025

Enliven Therapeutics (NASDAQ:ELVN) Trading 5.3% HigherWhat's Next? - MarketBeat

Sep 22, 2025

Sep 22, 2025

Published on: 2025-09-22 00:22:41 - newser.com

Sep 22, 2025

Sep 21, 2025

Rhumbline Advisers Acquires 2,466 Shares of Enliven Therapeutics, Inc. $ELVN - Defense World

Sep 21, 2025